Abstract
Our objective was to assess thermogenic action of fluoxetine (FL) in obese menopausal women, evaluating the effect of FL administration on resting energy expenditure (REE) and on glucose-induced thermogenesis both after acute administration (40 mg in single dose the evening before measurements) and after a 12- week period of diet treatment plus FL (60 mg per day) or placebo. It was a double-blind, placebo-controlled design both in acute and in chronic study. The subjects were 32 obese, otherwise healthy, menopausal women. The patients were assigned randomly to three groups, one performing an acute study protocol, in which resting and glucose-induced thermogenesis was measured after FL and placebo administration, performed in randomised order. The other two groups underwent dietary plus pharmacological treatment (FL or placebo, PL). Resting and glucose-induced thermogenesis was measured at baseline and after 12 weeks of treatment. The results showed that acute FL administration caused an increase in resting energy expenditure (PL: 5.35±0.18 vs FL: 5.53±0.24 KJ/min, p<0.05). A significant decrease of REE was observed in the PL group after 12 weeks (p<0.03), while a slight, but not significant, decrease was observed in the FL group (p=NS). FL did not affect thermic response to oral glucose neither after acute nor chronic administration (p=NS for all groups studied). The conclusion was that our data give support to thermogenic actions of FL after acute administration, suggesting also that chronic FL treatment may restrain to some degree the metabolic adaptation expected during weight loss in obese subjects. At variance with what observed with other drugs, such as dexfenfluramine, an increased thermic effect of oral glucose does not seem to be involved in the thermogenetic action of FL.
Similar content being viewed by others
References
Wilber J.F. Neuropeptides, appetite regulation, and human obesity. JAMA 1991, 266: 257–259.
Troiano R.P., Flegal K.M., Kuczmarsky R.J., Campbell S.M., Johnson C.L. Overweight prevalence and trends for children and adolescents: the National Health and Nutrition Examination Survey, 1963 to 1991. Arch. Pediatr. Adolesc. Med. 1997, 149: 1085–1091.
Leibowitz S.F., Weiss G.F., Shor-Posner G. Medial hypothalamic serotonin in the control of eating behaviour. Pharmacol. Biochem. Behav. 1985, 23: 541–550.
Blundell J.E., Hill A.J. Serotoninergic modulation of the pattern of eating and the profile of hunger-satiety in humans. Int. J. Obes. 1987, 11 (Suppl. 3): 141–155.
Stark P., Hardison C.D. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorders. J. Clin. Psychiatry 1985, 46: 7–13.
Stark P., Fuller R.W., Wong D.T. The pharmacologic profile of fluoxetine. J. Clin. Psychiatry 1985, 46: 7–13.
Greeno C.G., Wing R.R. A double-blind placebo controlled trial of the effect of fluoxetine on dietary intake in overweight women with and without binge-eating disorders. Am. J. Clin. Nutr. 1996, 64: 267–273.
Visser M., Seidell J.C., Koppeschaar H.P.F., Smits P. The effect of fluoxetine on body weight, body composition and visceral fat accumulation. Int. J. Obes. 1993, 17: 247–253.
Ferguson J.M., Feighner G.P. Fluoxetine-induced weight loss in overweight nondepressed humans. Int. J. Obes. 1987, 11 (Suppl. 3): 163–170.
Levine L.R., Rosenblatt S., Bosomworth J. Use of a serotonine re-uptake inhibitor, fluoxetine, in the treatment of obesity. Int. J. Obes. 1987, 11 (Suppl. 3): 185–190.
Levine L.R., Enas G.G., Thompson W.L., Byyny R.L., Daver A.D., Kirby R.W., Kreindler T.G., Levy B., Lucas C.P. Use of fluoxetine, a selective serotonine uptake inhibitor, in the treatment of obesity: a dose response study. Int. J. Obes. 1989, 13: 635–645.
Bross R., Hoffer L.J. Fluoxetine increases resting energy expenditure and basal body temperature in humans. Am. J. Clin. Nutr. 1995, 61: 1020–1025.
Stinson J.C., Murphy C.M., Andrews J.F., Tomkin G.H. An assessment of the thermogenic effects of fluoxetine in obese subject. Int. J. Obes. 1992, 16: 391–395.
Pohelman E., Goran M.I., Gardner A.W., Ades P.A., Arciero P.J., Katzman-Rooks S.M., Montgomery S.M., Toth M.J., Sutherland P.T. Determinants of decline in resting metabolic rate in aging females. Am. J. Physiol. 1993, 264: E450–E455.
Gardner A.W., Pohelman E.T. Physical activity is a significant predictor of body density in middle-aged and older males. Am. J. Clin. Nutr. 1993, 57: 8–14.
Webb P. 24-hours energy expenditure and the menstrual cycle. Am. J. Clin. Nutr. 1986, 44: 614–619.
Mateux P., Ducros F., Bourque J., Garon J., Chiasson J.L. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int. J. Obes. 1997, 21: 97–102.
Darga L.L., Carrol-Michals L., Botsford S.J., Lucas C.P. Fluoxetine’s effect on weight loss in obese subjects. Am. J. Clin. Nutr. 1991, 54: 321–325.
Mansell P.I., Macdonald I.A. Reappraisal of the Weir equation for calculation of metabolic rate. Am. J. Physiol. 1990, 27: R1347–R1354.
Gray D.S., Fujioka K., Dewine W., Bray G.A. Fluoxetine treatment of the obese diabetic. Int. J. Obes. 1992, 16: 193–198.
O’Kane M., Wiles P.G., Wales J.K. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabetic Med. 1994, 11: 105–110.
Chiasson L., Law D.C.W., Leiter L.A., Tildesley H.D., Birmingham C.L., Ekoe J.M., Hamet P., et al. Fluoxetine has potential in obese NIDDM-multicentre Canadian trial. Diabetes 1989, 38: 154A.
Wise S.D. Clinical studies with fluoxetine in obesity. Am. J. Clin. Nutr. 1992, 55: 1815–1845.
Aronoff G.R., Bergstrom R.F., Pottratz S.T., Sloan R.S., Wolen R.L., Lemberger L. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin. Pharmacol. Ther. 1984, 36: 138–144.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bondi, M., Menozzi, R., Bertolini, M. et al. Metabolic effects of fluoxetine in obese menopausal women. J Endocrinol Invest 23, 280–286 (2000). https://doi.org/10.1007/BF03343724
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343724